Pronounced anti-proliferative activity and tumor cell selectivity of 5-alkyl-2-amino-3-methylcarboxylate thiophenes
作者:Joice Thomas、Alenka Jecic、Els Vanstreels、Lizette van Berckelaer、Romeo Romagnoli、Wim Dehaen、Sandra Liekens、Jan Balzarini
DOI:10.1016/j.ejmech.2017.03.044
日期:2017.5
mid-nanomolar range with 500- to 1000-fold tumor cell selectivity. The compounds preferentially inhibited the proliferation of T-lymphoma CEM and Molt/4, prostate PC-3, kidney Caki-1 and hepatoma Huh-7 tumor cells, but were virtually inactive against other tumor cell lines including B-lymphoma Raji and cervix carcinoma HeLa cells. The novel prototype drug 3j (containing a 5-heptyl chain) elicited a cytotoxic
5-(2-(4-甲氧基苯基)乙基)-2-氨基-3-甲基羧酸噻吩(TR560)是最近发现的新型肿瘤选择性化合物的原型药物,该化合物优先抑制特定肿瘤细胞类型的增殖(例如白血病/淋巴瘤)。在这里,我们通过用烷基链取代4-甲氧基苯基部分来简化分子,从而进一步提高了肿瘤的选择性。几种在C-5处含有至少6个(己基)至9个(壬基)碳单元的烷基的2-氨基-3-甲基羧酸盐噻吩衍生物在500-1000的中纳摩尔范围内表现出显着的抗增殖活性。倍的肿瘤细胞选择性。这些化合物优先抑制T淋巴瘤CEM和Molt / 4,前列腺PC-3,肾Caki-1和肝癌Huh-7肿瘤细胞的增殖,但实际上对其他肿瘤细胞系(包括B淋巴瘤Raji和宫颈癌HeLa细胞)无活性。新型原型药物3j(包含5-庚基链)已在暴露4小时后引起细胞毒性而不是细胞抑制活性。异常的肿瘤选择性无法通过敏感肿瘤细胞与耐药肿瘤细胞对药物的差异吸收(或外排)来解释。